Drug Delivery
HYDROGEL COMPOSITIONS FOR USE FOR DEPLETION OF TUMOR ASSOCIATED
MACROPHAGES
WARF: P210433US02
Inventors: Quanyin Hu, Yingyue Ding, Zhaoting Li
The Invention
UW-Madison researchers have developed a biocompatible alginate-based hydrogel containing Pexidartinib (PLX) loaded nanoparticles (PLX-NPs) alone or in combination with platelet conjugated aPD-1 (P-aPD-1). Upon application at the tumor site, the hydrogel gradually releases PLX, which blocks colony-stimulating factor 1 (CSF1) receptors to effectively deplete TAMs. The decrease in TAMs results in a favorable milieu for facilitating local or systemic delivery of P-aPD-1. The successful delivery/release of aPD-1 blocks the PD-1/PDL-1 pathway, thereby reactivating T cells.
Successful and efficient delivery of aPD-1 has been shown to inhibit post-surgery tumor recurrence.